Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Enicepatide in Generally Healthy Adult Chinese Participants
Sponsor: Hoffmann-La Roche
Summary
This is a Phase I, randomized, double-blinded, placebo-controlled, study to assess the safety, tolerability, and pharmacokinetics (PK) of enicepatide in generally healthy adult Chinese participants with body mass index (BMI) ≥23.0 kilograms per meter squared (kg/m\^2).
Official title: A Phase I, Randomized, Double-Blinded, Placebo-Controlled, Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Enicepatide in Adult Chinese Participants With Body Mass Index ≥23.0 kg/m2
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
36
Start Date
2026-07-02
Completion Date
2027-05-14
Last Updated
2026-10-06
Healthy Volunteers
Yes
Conditions
Interventions
Enicepatide
Participants will receive enicepatide via subcutaneous (SC) injection as per the schedule in the protocol.
Placebo
Participants will receive matching placebo via subcutaneous (SC) injection as per the schedule in the protocol.
Locations (1)
Peking University First Hospital
Beijing, China